NO20052987D0 - Forbindelser for normalisering av sovn/vaken-syklusen. - Google Patents

Forbindelser for normalisering av sovn/vaken-syklusen.

Info

Publication number
NO20052987D0
NO20052987D0 NO20052987A NO20052987A NO20052987D0 NO 20052987 D0 NO20052987 D0 NO 20052987D0 NO 20052987 A NO20052987 A NO 20052987A NO 20052987 A NO20052987 A NO 20052987A NO 20052987 D0 NO20052987 D0 NO 20052987D0
Authority
NO
Norway
Prior art keywords
normalizing
sleep
compounds
wake cycle
wake
Prior art date
Application number
NO20052987A
Other languages
English (en)
Other versions
NO20052987L (no
Inventor
Scott Lukas
Perry F Renshaw
Original Assignee
Mclean Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mclean Hospital Corp filed Critical Mclean Hospital Corp
Publication of NO20052987D0 publication Critical patent/NO20052987D0/no
Publication of NO20052987L publication Critical patent/NO20052987L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20052987A 2002-12-20 2005-06-17 Forbindelser for normalisering av sovn/vaken-syklusen. NO20052987L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43545702P 2002-12-20 2002-12-20
PCT/US2003/040450 WO2004058160A2 (en) 2002-12-20 2003-12-17 Compounds for the normalization of the sleep/wake cycle

Publications (2)

Publication Number Publication Date
NO20052987D0 true NO20052987D0 (no) 2005-06-17
NO20052987L NO20052987L (no) 2005-08-29

Family

ID=32682243

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052987A NO20052987L (no) 2002-12-20 2005-06-17 Forbindelser for normalisering av sovn/vaken-syklusen.

Country Status (12)

Country Link
US (1) US20040176316A1 (no)
EP (1) EP1589979A4 (no)
JP (2) JP4717444B2 (no)
CN (1) CN100563660C (no)
AU (1) AU2003299715A1 (no)
BR (1) BR0317586A (no)
CA (1) CA2508995A1 (no)
MX (1) MXPA05006781A (no)
NO (1) NO20052987L (no)
RU (1) RU2366428C2 (no)
UA (1) UA88869C2 (no)
WO (1) WO2004058160A2 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
BR0316054A (pt) * 2002-11-08 2005-09-20 Mclean Hospital Corp Compostos para tratamento de dependência e privação de tabaco
US20050113449A1 (en) * 2003-10-08 2005-05-26 Renshaw Perry F. Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
AU2004317087A1 (en) * 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
US7737128B2 (en) * 2004-06-10 2010-06-15 The Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1765364A4 (en) * 2004-06-10 2010-09-22 Mclean Hospital Corp PYRIMIDINES, SUCH AS Z: B: CYTIDINE, IN THE TREATMENT OF PATIENTS WITH BIPOLAR DISORDER
WO2006020703A1 (en) * 2004-08-11 2006-02-23 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
PT1888081T (pt) * 2005-05-23 2017-03-01 Massachusetts Inst Technology Composições contendo pufa e seus métodos de utilização
TW200827367A (en) * 2006-10-26 2008-07-01 Kyowa Hakko Kogyo Kk A therapeutic agent for irritable bowel syndrome
WO2009065119A2 (en) * 2007-11-16 2009-05-22 Bio Clinical Development, Inc. Edible energy composition with low caffeine
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
JP5426918B2 (ja) * 2009-04-20 2014-02-26 株式会社 伊藤園 ウリジンを含有する抗疲労剤又は体力向上剤
JP2011032232A (ja) * 2009-08-04 2011-02-17 Ito En Ltd 興奮抑制用又は鎮静用組成物及びこれを含む飲食品
JP5989319B2 (ja) 2011-10-06 2016-09-07 ライオン株式会社 睡眠の質改善剤
AU2013273263B2 (en) * 2012-06-04 2017-08-24 Pfizer Inc. Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders
CN105101974B (zh) * 2013-04-05 2018-07-03 狮王株式会社 内服组合物
EP3056096B1 (de) * 2015-02-05 2019-07-24 Smart Sleep GmbH Verwendung eines Nahrungsergänzungsmittels enthaltend Kreatin zur Reduktion des natürlichen Schlafbedarfs oder zur schnelleren Anpassung der zirkadianen Rhythmik an neue Zeitzonen
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4048316A (en) * 1974-03-04 1977-09-13 Penn Nathar W Composition for antagonizing the narcotic effects of barbiturate addiction and withdrawal effects, and for treatment of barbiturate poisoning
US4115576A (en) * 1974-04-02 1978-09-19 Penn Nathar W Compositions and method of employing the same for inhibiting alcohol intoxication
US4027017A (en) * 1974-07-16 1977-05-31 Chugai Seiyaku Kabushiki Kaisha Method of treating alcoholism
IT1200589B (it) * 1985-02-14 1989-01-27 Gibipharma Spa Derivati naturali attivita farmagologica
JPS63208524A (ja) * 1987-02-25 1988-08-30 Nippon Oil & Fats Co Ltd 睡眠リズム改善剤
US5691320A (en) * 1987-10-28 1997-11-25 Pro-Neuron, Inc. Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis
JPH0418034A (ja) * 1990-05-11 1992-01-22 Kanegafuchi Chem Ind Co Ltd 点眼組成物
US5635486A (en) * 1990-05-11 1997-06-03 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Ophthalmic composition comprising a sleep adjusting substance
EP0588917B1 (en) * 1991-05-29 2000-11-08 Abbott Laboratories Isoxazole and isothiazole compounds that enhance cognitive function
US5704361A (en) * 1991-11-08 1998-01-06 Mayo Foundation For Medical Education And Research Volumetric image ultrasound transducer underfluid catheter system
GB9200293D0 (en) * 1992-01-08 1992-02-26 Wyeth John & Brother Ltd Piperazine derivatives
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
US5472958A (en) * 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
AU5304796A (en) * 1995-03-06 1996-09-23 Interneuron Pharmaceuticals, Inc. Reduction of infarct volume using citicoline
AU4070597A (en) * 1996-08-16 1998-03-06 The Texas A & M University System Modifying insect cell gylcosylation pathways with baculovirus expression vectors
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
US5958896A (en) * 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
US6153653A (en) * 1997-11-26 2000-11-28 Protarga, Inc. Choline compositions and uses thereof
US5977174A (en) * 1997-11-26 1999-11-02 Neuromedica, Inc. Cholinergic compositions and uses thereof
DK2145627T3 (da) * 1998-07-31 2014-07-21 Massachusetts Inst Technology Anvendelse af uridin i kombination med cholin til behandling af en humør-lidelse eller en følelsesmæssig lidelse.
DE19929995B4 (de) * 1999-06-30 2004-06-03 Skw Trostberg Ag Verwendung von Kreatin und/oder Kreatin-Derivaten zur Behandlung von Befindlichkeitsstörungen bei Frauen
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
ES2170649B1 (es) * 2000-03-29 2003-06-16 Ferrer Int Uso de la cdp-colina en el tratamiento de la abstinencia alcoholica.
US6277855B1 (en) * 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
US20030114415A1 (en) * 2001-12-14 2003-06-19 Wurtman Richard J. Compositions and methods for treating and preventing memory impairment using citicoline

Also Published As

Publication number Publication date
WO2004058160A2 (en) 2004-07-15
JP2011102319A (ja) 2011-05-26
MXPA05006781A (es) 2005-09-30
RU2366428C2 (ru) 2009-09-10
WO2004058160A3 (en) 2005-03-31
CA2508995A1 (en) 2004-07-15
UA88869C2 (ru) 2009-12-10
NO20052987L (no) 2005-08-29
JP4717444B2 (ja) 2011-07-06
BR0317586A (pt) 2005-11-22
EP1589979A2 (en) 2005-11-02
CN100563660C (zh) 2009-12-02
EP1589979A4 (en) 2009-04-01
AU2003299715A1 (en) 2004-07-22
JP2006513214A (ja) 2006-04-20
RU2005122934A (ru) 2006-01-20
US20040176316A1 (en) 2004-09-09
AU2003299715A8 (en) 2004-07-22
CN1750833A (zh) 2006-03-22

Similar Documents

Publication Publication Date Title
NO20052987D0 (no) Forbindelser for normalisering av sovn/vaken-syklusen.
NO20053248D0 (no) Kerosenblanding.
NO20052248D0 (no) Svivelstykkesystem.
DE60315471D1 (de) 2,5-disubstituierte 3-mercaptopentansaure
DE60324703D1 (de) Barbitursäure derivaten.
BRPI0308677A2 (pt) condensador.
NO20051500D0 (no) Substituerte heterocyklylpyrimidiner.
ITMI20032170A1 (it) Tagliacimosse.
ITMI20022179A1 (it) Il manopoliero
NO20051497D0 (no) Beta-laktamaseinhibitorprodrug.
ITMI20021328A1 (it) Nuove piperazine 1,4 - disostituite
ES1053179Y (es) Salvavidas perfeccionado.
ITRA20020023A1 (it) Il mollino.
ES1052590Y (es) Quiosco-consigna.
ES1051803Y (es) Andamio perfeccionado.
NL1024812A1 (nl) Lampenkap.
ES1052052Y (es) Brida.
ES1051950Y (es) Celosia fija.
ES1050939Y (es) Celosia antivandalica.
ES1053801Y (es) Salvavidas perfeccionado.
FI20020644A0 (fi) Kompleksiliuos
MA25629A1 (fr) Reacteur : aero-hydro-electrique.
ES1051515Y (es) Estuche perfeccionado.
ITSS20020004A1 (it) Paella algherese.
ITRM20030320A0 (it) Perfezionamenti ai serramenti.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application